Status:
UNKNOWN
Amyloidosis Incidence in High-Risk Cardiac Device Patients
Lead Sponsor:
Midwest Heart & Vascular Specialists
Conditions:
Amyloid
Cardiac Amyloidosis
Eligibility:
All Genders
40+ years
Brief Summary
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat ti...
Detailed Description
The study targets a key gap in cardiac amyloidosis diagnosis by systematically evaluating the histopathological incidence of the disease using chest wall fat pad biopsies-tissue that is typically disc...
Eligibility Criteria
Inclusion
- Patients who are 40 years of age or older
- Patients who are able and willing to provide informed consent
- Patients who are scheduled for CIED implantation within the study period and with clinical lab and imaging features suggestive of cardiac amyloidosis
Exclusion
- Individuals below the age of 40.
- Persons who are unable to consent or who do not consent to participate.
- Patients who have already been diagnosed with cardiac amyloidosis prior to the study
Key Trial Info
Start Date :
January 29 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06186167
Start Date
January 29 2024
End Date
December 31 2024
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Midwest Heart & Vascular Specialists
Overland Park, Kansas, United States, 66211